DECONGEST-AHF: Vasodilatation or Loop Diuretics in Acute Heart Failure
A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 1041 participants.
Also called NCT05276219
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 1,041 participants
- Sponsor
- Registry
-
NCT05276219 -
2022-500035-36-01
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Denmark
- Registry status
- Recruiting
Technical summary
Registry record NCT05276219. Randomized; quadruple masking; primary purpose treatment. Start 2023-09-14 (actual); primary completion 2027-05-01 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- DECONGEST-AHF: Vasodilatation or Loop Diuretics in Acute Heart Failure
- Acronym
- DECONGEST-AHF
- Condition
- Pulmonary Edema
- Condition
- Congestive Heart Failure
- Condition
- Acute Heart Failure
- Intervention (Drug)
- Furosemide Injection
- Intervention (Drug)
- Isosorbide Dinitrate
- Intervention (Drug)
- Furosemide and isosorbide dinitrate
- Lead sponsor
- Copenhagen University Hospital, Rigshospitalet
- Collaborator
- Zealand University Hospital
- Collaborator
- Copenhagen University Hospital, Hvidovre
- Collaborator
- Herlev Hospital
- Collaborator
- Bispebjerg Hospital
Record details
- Record id
cardio:ct-nct05276219- Content hash
21ea019692d3fa2608162ad36c93c2669f0583221256d91106009f84557fe7fc